Company intelligence / Profile preview

Tempero Bio

Oakland, California, United Statestemperobio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

TMP-301, the company's lead candidate, has been evaluated in over 80 healthy volunteers in Phase 1 trials with an acceptable safety and tolerability profile and demonstrated robust receptor occupancy via PET imaging. The company has initiated a Phase 2 trial for alcohol use disorder and plans to initiate studies for cocaine use disorder.

Therapeutic areas: Psychiatry
Modalities: Small moleculesmGluR5 negative allosteric modulators (NAMs)
Industry: Biotech

Drug pipeline

2 assets

TMP-301

1 more asset in the full pipeline.

Request access →

Partnerships

Nxera Pharma (formerly Sosei Heptares)

Beyond the preview

Go deeper on Tempero Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tempero Bio.

Explore the full profile